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460 TABLE 1 Comparison of selected rapid antibody cassette tests for severe acute respiratory syndrome coronavirus 2 (continued on the next page)
Test Manufacturer Sensitivity Specificity Total accuracy Recommended 
sample type
Sample size Time




IgG: 99.3%; IgM: 98.6% IgG: 98.9%; IgM: 96.1% serum, plasma, 
whole blood
10 μl 10 min
2019 ‑nCoV IgG / IgM Rapid Test Cassette 
(Whole Blood / Serum / Plasma)
Hangzhou AllTest 




IgG: 98%; IgM: 96% IgG: 98.6%; IgM: 92.9% serum, plasma, 
whole blood
10 μl of serum or 
plasma; 20 μl of 
fingertip blood or 
whole blood
10 min
Rapid test 2019 ‑nCOV blood myLAB, Poland – – – whole blood 20 μl 10 min




IgG: 100%; IgM: 100% – serum, plasma, 
whole blood
10 μl 15 min
Novel Coronavirus (2019 ‑nCoV) Antibody 
IgG / IgM Assay (Colloidal Gold)
Avioq Biotechnology 
Co., Ltd., China
– – – serum, plasma, 
whole blood
10 μl 15 min
2019 ‑nCoV IgG & IgM Antibody Determination Kit Beijing Diagreat 
Biotechnologies Co., 
Ltd., China
– – – serum, plasma, 
whole blood
– 15 min
COVID ‑19 IgM / IgG Rapid Test BioMedomics, Inc., 
United States




OnSite COVID ‑19 IgG / IgM Rapid Test CTK Biotech, Inc., 
United States
96.9% 99.4% – – – 10 min
STANDARD Q COVID ‑19 IgM / IgG Duo SD BIOSENSOR, Inc., 
Korea
81.8% 96.6% – serum, plasma, 
whole blood
10 μl 10–15 min
2019 ‑Novel Coronavirus (2019 ‑nCoV) IgG / IgM 











99.8% (plasma: 100%; serum: 
99.39%; whole blood: 100%)
94.68% serum, plasma, 
whole blood
10 μl 10–15 min
VivaDiagTM COVID ‑19 IgM / IgG Rapid Test VivaChek 
Laboratories, Inc., 
United States
100% Infection time, 4–10 days; IgM and 
IgG: 81.25%
Infection time, 11–24 days; IgM 
and IgG: 97.1%
Infection time, 4–10 days; IgM and 
IgG: 94.6%
Infection time, 11–24 days; IgM and 
IgG: 99.3% and 95.1%, respectively
whole blood 10 μl 15 min
SARS ‑CoV ‑2 IgG / IgM Rapid Qualitative Test Kit Xiamen Biotime 
Biotechnology Co., 
Ltd., China
– – – – 10 μl 10–15 min
One Step Test for Novel Coronavirus 
(2019 ‑nCoV) IgM / IgG Antibody
Getein Biotech, Inc., 
China
94.1% 95.1% – serum, plasma, 
fingertip blood, 
whole blood
10 μl of serum or 
plasma; 20 μl of 
fingertip blood or 
whole blood
10–20 min
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